Ridgefield, CT, USA is Boehringer Ingelheim's 3rd largest research sit, where scientists are tackling some of the most difficult challenges in healthcare.
Our Code of Conduct sets the ethical standards that guides all our business activities. It´s about all of us. Each individual plays a vital role in bringing the Code of Conduct to live.
Established in 2015 and jointly sponsored by BI and the BI Venture Fund, the prize allows recipients to focus on development of breakthrough medicines.
Rising Star Leads with Determination | Boehringer Ingelheim US
Click to find out more on our partnership with the HBA, where we honor a BI colleague as a “Rising Star” to support the advancement of women in health care.
Fighting Non-Communicable Diseases | Boehringer Ingelheim US
Read more on Boehringer Ingelheim's new NCD initiative, aiming to reduce NCD prevalence and capture the impact of our product portfolio for our patients.
The Lyon region is a key global hub for the Animal Health business of the company, encompassing research, development, production and supply of veterinary products.
Jardiance® (empagliflozin) Proven to Reduce Risk of Cardiovascular Death | BI US
Find out more about how the use of JARDIANCE has proven to reduce the combined relative risk of cardiovascular death and hospitalization for heart failure by 25%.